eprintid: 10151872
rev_number: 8
eprint_status: archive
userid: 699
dir: disk0/10/15/18/72
datestamp: 2022-07-12 15:44:45
lastmod: 2024-10-25 15:47:56
status_changed: 2022-07-12 15:44:45
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Flynn, Michael J
creators_name: Ledermann, Jonathan A
title: Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
ispublished: pub
subjects: UCH
divisions: C10
divisions: G99
divisions: B02
divisions: UCL
divisions: D19
keywords: DNA damage response, PARP inhibitors, Platinum resistance, VEGF inhibitors, immune checkpoint inhibitors
note: © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
abstract: Definitions of platinum resistance have been questioned and changed over the last five years, even though no predictive biomarker of resistance exists. These have sculpted how we approach platinum retreatment and, consequently, how we devise new treatment strategies for those patients with tumour progression on platinum therapy. Platinum-non-eligible ovarian cancer is treated with single-agent non-platinum drugs. When bevacizumab can be added to chemotherapy, progression-free survival improves significantly. For patients with a BRCA mutation, PARP inhibitor monotherapy is an option compared to chemotherapy. There is currently no clearly identified role for immune-checkpoint inhibition in this patient population. This review describes some of the challenges in treating patients with platinum resistance and suggests refinements in the selection of patients most likely to benefit from targeting a DNA damage response, angiogenesis or immune modulation. It also describes novel agents of interest and possible mechanisms of the synergy of therapeutic combinations.
date: 2022-05-12
date_type: published
publisher: OAE Publishing Inc.
official_url: https://dx.doi.org/10.20517/cdr.2022.13
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1964910
doi: 10.20517/cdr.2022.13
medium: Electronic-eCollection
lyricists_name: Ledermann, Jonathan
lyricists_id: JALED70
actors_name: Kalinowski, Damian
actors_id: DKALI47
actors_role: owner
full_text_status: public
publication: Cancer Drug Resistance
volume: 5
number: 2
pagerange: 424-435
event_location: United States
citation:        Flynn, Michael J;    Ledermann, Jonathan A;      (2022)    Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer.                   Cancer Drug Resistance , 5  (2)   pp. 424-435.    10.20517/cdr.2022.13 <https://doi.org/10.20517/cdr.2022.13>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10151872/1/Ledermann_Ovarian%20cancer%20recurrence_VoR.pdf